The merger, backed by an oversubscribed $180 million private placement, will fund development of NOR-101, an IL-13 x IL-18 bispecific antibody entering phase 1 trials in atopic dermatitis in early 2027.
|Videos|May 4, 2020
Biologic use in the era of COVID-19
Author(s)Jessica Barry
This week, we spoke with Mark Lebwohl, M.D., about his recent article featured in the Journal of the American Academy of Dermatology regarding biologic use in dermatology patients during the COVID-19 pandemic.
Advertisement
This week, we spoke with Mark Lebwohl, M.D., Waldman Professor and Chair, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, about his recent article featured in the Journal of the American Academy of Dermatology regarding biologic use in dermatology patients during the COVID-19 pandemic.
Advertisement
Related to this article
Maui Derm NP+PA Fall 2026 brought APPs together for updates spanning inflammatory disease, oncology, emerging therapies, and diagnostic challenges.
Faculty from the Cutaneous Oncology Workshop answer practical questions spanning skin cancer prevention, diagnosis, treatment, and follow-up.
Two new Neutrogena facial sunscreens incorporate bemotrizinol, the first new sunscreen active ingredient added to the US OTC monograph in decades.
This review of the latest dermatological studies includes insights on stem cell therapies for skin rejuvenation, smoke exposure in HS, hair loss in pediatric IBD, and more.
An HS toolbox with wound care, symptom relief, and personal care supplies can help patients stay prepared for unexpected flares.
Dermatitis-related adverse events vary widely across atopic dermatitis systemic trials, driven by disease fluctuation and reporting differences, informing patient counseling and flare definitions.
The inaugural workshop explored skin cancer care from prevention and diagnosis through systemic therapy, radiation, and multidisciplinary management.
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Topical Solution Shows Long-Term Promise for Male Pattern Hair Loss
2
Neutrogena Launches New Sunscreens With Newly Permitted UV Filter Bemotrizinol
3
Dersimelagon NDA Accepted by FDA with Priority Review for EPP, XLP
4
Targeted Skincare, Dermabrasion Show Skin Quality Improvements During Medical Weight Loss
5